Companies · KE
Kimball Electronics
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 5, 2026
Kimball Electronics reports Q1 FY2027 7% YoY sales growth; medical CDMO ramp and Helvoet integration on track.
Kimball Electronics delivered Q1 FY2027 net sales of $391 million, up 7% year-over-year, driven by organic medical growth of 9% and the Helvoet acquisition contribution of $12.4 million. Medical now represents 29% of revenue and is tracking double-digit growth momentum. The Indianapolis medical CDMO facility transfer remains on budget and on schedule, with production expected to start in December. Management reiterates full-year sales guidance at the high end of the $1.535–$1.560 billion range, citing strong core medical performance offsetting automotive softness in North America. Gross margin remained flat at 7.9% despite favorable mix, constrained by elevated material and component costs and the near-term drag from Indianapolis ramp.
Tone: bullishRevenue
$1.4B
KE 10-K · FY 2026
Employees
5,600
Revenue FY2025
$1.5B
Founded
1961
Profile
KE 10-K Item 1 · Aug 19, 2026Kimball Electronics is a global contract manufacturer providing electronics manufacturing services (EMS) and contract development and manufacturing organization (CDMO) solutions to customers in the automotive, medical, and industrial end markets. The company has expanded beyond traditional EMS into medical disposables, drug delivery devices, and precision molded plastics through its Kimball Solutions platform. It operates eleven manufacturing facilities across the United States, China, India, Mexico, the Netherlands, Poland, Romania, and Thailand.
Read filing description ↓ Collapse description ↑
Kimball Electronics delivers a package of value that includes durable, high-reliability electronics, higher level and final assemblies, and contract development and manufacturing organization ('CDMO') solutions. Through our Kimball Solutions platform, we provide integrated manufacturing solutions that combine electronics manufacturing services, medical disposables, drug delivery solutions, precision molded plastics, and end-to-end product lifecycle support. Our CDMO solutions support the production of medical disposables and drug delivery devices, from precision molded plastics and cold chain management to drug integration. The acquisition of Helvoet Polymer Technologies B.V. ('Helvoet') on July 1, 2026, which occurred after our fiscal year end and is therefore reported as a subsequent event in Note 22 - Subsequent Event of Notes to Consolidated Financial Statements, expanded our capabilities in precision molded plastics, complex tooling, and medical device component manufacturing, enhancing our ability to provide comprehensive solutions to customers across the medical and pharmaceutical markets. Customers and industry trade publications regularly award us for our design, engineering, and manufacturing expertise that, coupled with robust processes and procedures, help us ensure that we deliver the highest levels of quality, reliability, and innovative service throughout the entire life cycle of our customers' products. Our Customer Relationship Management ('CRM') model is key to providing our customers convenient access to our highly integrated global footprint, enabled by our largely standardized operating system and procedures.
Primary products
- Production and testing of printed circuit board assemblies (PCBAs)
- High-level and final assembly of medical, automotive, and industrial products
- Design services and support, including innovative Design for Excellence solutions
- Supply chain services and support
- Rapid prototyping and new product introduction support
- Product design and process validation and qualification
Business segments
End markets
Geographies
Named customers
For fiscal year 2026, sales to our three largest customers — Nexteer Automotive, Philips, and ZF — accounted for approximately 40% of our net sales in the aggregate, and sales to Nexteer Automotive alone accounted for approximately 18% of our net sales.
Named competitors
“We enjoy a unique market position between these extremes which allows us to compete with the larger scale players for high-volume projects, but also maintain our competitive position in the generally lower volume durable electronics market space.” Competitive position, as stated in the filing
Revenue commentary · FY 2026
Net sales in fiscal year 2026 decreased 4% compared to fiscal year 2025, driven primarily by decreases in the automotive and industrial vertical markets partially offset by an increase in the medical market.
The rest of KE is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.